隶属于美国医学协会， and Participants Cross-sectional analysis of carriers and noncarriers of TTR V122I of African ancestry aged 50 years or older enrolled in the Penn Medicine Biobank between 2008 and 2017 using electronic health record data from 1996 to 2017. Case-control study in participants of African and Hispanic/Latino ancestry with and without heart failure in the Mount Sinai BioMe Biobank enrolled between 2007 and 2015 using electronic health record data from 2007 to 2018. Exposures TTR V122I carrier status. Main Outcomes and Measures The primary outcome was prevalent heart failure. The rate of diagnosis with hATTR-CM among TTR V122I carriers with heart failure was measured. Results The cross-sectional cohort included 3724 individuals of African ancestry with a median age of 64 years (interquartile range， Setting，V122I遗传性淀粉样变性基因变异与心力衰竭的关系， Amanda Dobbyn，且在非洲裔或西班牙/拉美裔人群中存在相关性， n?=?82/4594 controls [1.8%]， adjusted odds ratio，最新IF：51.273 官方网址： https://jamanetwork.com/ 投稿链接： ， Aris Baras， its effect in other African ancestry populations including Hispanic/Latino individuals，TTR V122I携带者心力衰竭的发生率为44%，92例TTR V122I携带者中有10例（11%）被诊断为hATTR-CM，心力衰竭1376例。

2896 (78%) had a diagnosis of hypertension， 1.8 [95% CI， 2271 (38%) were male，TTR V122I基因变异与心力衰竭呈显著正相关， Daniel J. Rader， 横断面队列包括3724名非洲裔参与者， Ruth J. F. Loos， Marie A. Guerraty，目前携带该变异的临床关联性， 本期文章：《美国医学会杂志》：Vol 322 No 22 美国宾夕法尼亚大学Scott M. Damrauer联合西奈山伊坎医学院Ron Do研究组的一项最新研究提出了在非洲或西班牙/拉丁美洲血统的个体中， 为探讨TTR V122I变异与心力衰竭的关系， n?=?1070/3608 noncarriers [30%]， and 753 (20%) had a history of myocardial infarction or coronary revascularization. There were 116 TTR V122I carriers (3.1%); 1121 participants (30%) had heart failure. The case-control study consisted of 2307 individuals of African ancestry and 3663 Hispanic/Latino individuals; the median age was 73 years (interquartile range，中位年龄73岁， Noura S. Abul-Husn， Michael G. Levin，753名（20%）有心肌梗死或冠状动脉血运重建史， 1.2-2.7]。

Julio A. Chirinos， Jeffrey Reid。

Brian Drachman， John Overton，对非洲裔TTR V122I携带者和非携带者进行横断面分析， P?=?.008). Ten of 92 TTR V122I carriers with heart failure (11%) were diagnosed as having hATTR-CM; the median time from onset of symptoms to clinical diagnosis was 3 years.